Vor Biopharma (NASDAQ:VOR) Posts Quarterly Earnings Results, Misses Expectations By $0.64 EPS

Vor Biopharma (NASDAQ:VOR) announced its quarterly earnings data on Friday. The company reported ($1.45) EPS for the quarter, missing the consensus estimate of ($0.81) by ($0.64), FiscalAI reports.

Vor Biopharma Price Performance

NASDAQ VOR opened at $19.68 on Friday. Vor Biopharma has a fifty-two week low of $6.50 and a fifty-two week high of $26.76. The business has a fifty day moving average of $20.75 and a 200-day moving average of $17.33.

Institutional Trading of Vor Biopharma

Large investors have recently made changes to their positions in the stock. Braidwell LP lifted its holdings in Vor Biopharma by 22.8% in the 2nd quarter. Braidwell LP now owns 573,104 shares of the company’s stock valued at $10,551,000 after purchasing an additional 106,330 shares in the last quarter. Renaissance Technologies LLC purchased a new stake in shares of Vor Biopharma during the first quarter worth about $2,298,000. Bank of America Corp DE grew its holdings in shares of Vor Biopharma by 28,408.1% during the first quarter. Bank of America Corp DE now owns 112,892 shares of the company’s stock worth $2,014,000 after buying an additional 112,496 shares in the last quarter. Bank of New York Mellon Corp acquired a new position in shares of Vor Biopharma in the second quarter valued at approximately $1,799,000. Finally, Simplify Asset Management Inc. acquired a new position in shares of Vor Biopharma in the first quarter valued at approximately $955,000. Institutional investors and hedge funds own 97.29% of the company’s stock.

Wall Street Analyst Weigh In

VOR has been the topic of several recent analyst reports. Wedbush upped their target price on shares of Vor Biopharma from $18.00 to $27.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 12th. Wall Street Zen downgraded shares of Vor Biopharma from a “hold” rating to a “sell” rating in a research report on Saturday. William Blair started coverage on shares of Vor Biopharma in a research report on Wednesday, October 21st. They set an “outperform” rating for the company. Citigroup raised Vor Biopharma to a “strong-buy” rating in a research note on Thursday, October 15th. Finally, Weiss Ratings upgraded Vor Biopharma from a “sell (d+)” rating to a “hold (c-)” rating in a report on Monday, September 14th. Two investment analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat, Vor Biopharma presently has a consensus rating of “Moderate Buy” and a consensus price target of $38.00.

Vor Biopharma Company Profile

Vor Biopharma Inc is a clinical-stage biotechnology company focused on developing engineered hematopoietic stem cell therapies for the treatment of cancer, particularly blood cancers. The company combines gene-editing technologies with targeted immunotherapies to address limitations associated with conventional cancer treatments.

Vor’s platform is designed to create engineered hematopoietic stem cells that can protect healthy blood-forming cells from targeted therapies. Its lead program, VOR33, is an investigational CD33-edited hematopoietic stem cell therapy intended to support the use of CD33-targeted treatments in patients with acute myeloid leukemia.